Hindawi Pain Research and Management Volume 2022, Article ID 1512616, 10 pages https://doi.org/10.1155/2022/1512616

Research Article

Risk Factors for Amputation in the Surgical Treatment of Hemophilic Osteoarthropathy: A 20-Year Single-Center Report

Yiming Xu, 1,2 Bin Feng, 1,2 Wei Zhu, 1,2 Yingjie Wang, 1,2 and Xisheng Weng, 1,2

Correspondence should be addressed to Xisheng Weng; xshweng@pumch.cams.cn

Received 19 December 2021; Revised 28 January 2022; Accepted 23 February 2022; Published 28 March 2022

Academic Editor: Jun Zou

Copyright © 2022 Yiming Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. Hemophilic osteoarthropathy (HO) is a common cause of spontaneous bleeding in hemophiliacs. Surgical procedures are necessary for patients with severe HO. As a last resort, amputation is sometimes needed to treat complex HO cases. This study aimed to review the existing records of patients who underwent amputations in HO surgical treatment, summarize the risk factors, and provide relevant references for surgeons. Methods. We retrospectively reviewed the records of hemophilic patients received surgeries at Peking Union Medical College Hospital between 2000 and 2020. The amputation patients without neoplasm or acute trauma were screened out. Patient information was extracted from medical records. A literature retrieval of hemophilic amputation cases was conducted via PubMed. The risk factors of amputation were summarized and analyzed via descriptive statistics and Fisher's precision probability test. Results. Four male hemophilia A patients out of 201 patients underwent lower limb amputation. The reasons of amputation contained severe pseudotumor with factor inhibitor and large bone defects, recurrent pathological fracture with pseudotumor, skin ulcer with chronic osteomyelitis, and pseudotumor with systematic infection. In cases reported in retrieved literature, severe pseudotumor with complications, bacterial infection and factor inhibitor were common factors. Discussion. As the first study on amputations in HO patients, we found that severe hemophilic pseudotumor, chronic bacterial infection, and coagulation factor inhibitor was potential risk factors for amputation. Sufficient factor replacement therapy is fundamental in the prevention of amputation. The early diagnosis and specially designed surgical techniques could improve the rate of limb salvage.

1. Introduction

Hemophilia comprises hereditary hemorrhagic disorders characterized by coagulation system deficiencies. The most common cause of hemophilia is coagulation factor VIII or IX deficiency, causing hemophilia A or B, respectively [1]. Coagulation factor deficiencies lead to spontaneous intra-articular or intramuscular bleeding. The persisting chronic stimulation of blood stasis causes musculoskeletal lesions called hemophilic osteopathic medicine (HO). Recurrent hemarthroses consequent to bleedings contributed to cartilage degeneration named hemophilic arthritis. [2]. Inappropriate treatment of intramuscular bleeding may cause soft tissue hematoma called hemophilic pseudotumor [3].

Hemophiliacs also have a higher prevalence of osteoporosis and pathological fractures [4, 5]. HO is associated with serious pain and motion dysfunction, especially in hemophiliacs administrated with limited hemostatic agents during childhood, and required surgical interventions for pain relief [6, 7].

With the developments of coagulation factor replacement therapy and perioperative management, hemophiliacs can receive safe surgical procedures. Total joint arthroplasty is used to treat end-stage hemophilic arthritis [8]. Surgical resection is applied in treating hemophilic pseudotumor [9]. In the early years, amputation of extremities was used in severe HO cases due to imperfect surgical technology [10]. Unfortunately, there are still amputation cases reported in modern literature, with no systematic summary for

¹Department of Orthopedics, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ²State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

amputation risk factors and prevention strategies [9, 11, 12]. In this study, we retrospectively evaluated amputation cases in the surgical treatment of HO, summarizing their clinical features and risk factors. As the first study on amputations in hemophilia patients, we hope that the result can provide a reference for surgeons facing the hard choice of limb salvage or amputation.

2. Materials and Methods

We retrospectively reviewed the medical records of hemophiliacs who underwent surgery for HO at Peking Union Medical College Hospital between 2000 and 2020. This study was approved by the appropriate institutional ethics review board. The patients who received amputation of extremity or joint disarticulation were screened out. Patients were excluded if the amputation was performed due to nonhemophilic diseases such as neoplasm or acute trauma. We recorded the following data: demographic data, type and severity of hemophilia, presence of factor inhibitor, aetiological antecedent, clinical preferences, and management. For all included amputation patients, follow-ups were performed by telephone, Internet, or interviews.

Because amputation is rare in hemophiliacs, we conducted literature retrieval using PubMed. The search terms contained "hemophilia," "amputation," and "disarticulation". The publication type was not limited. Clinical characteristics and amputation reasons of all reported cases were also recorded.

The results about amputation cases were shown in descriptive statistics and Fisher's precision probability test. Summary statistics were performed using Microsoft Excel 2016 (Microsoft, Redmond, WA) and SPSS Statistics 19.0 (SPSS Inc, Chicago, IL, US). Numerical data were summarized in tables as arithmetic means \pm standard deviation. Nominal and ordinal data are shown as frequencies with percentages. The level of significance was defined at p=0.05.

3. Results

- 3.1. General Characteristics. In total, 201 patients with 262 surgical procedures were included. Four patients underwent four amputation surgeries, with a prevalence of 1.99% (4/201). None of the patients suffered neoplasm or acute trauma, so no case was excluded (Table 1). All four amputation patients were male with hemophilia A: two of them had received regular factor replacement before and two only received factor replacement on demand. Factor inhibitor was found in one patient. Only one case directly received amputation rather than as a secondary procedure. From the literature, we identified 27 amputation cases from 14 papers published between 1992 and 2021. The majority of reported amputation cases had hemophilia A (23/27, 85.19%). Inhibitors were identified in seven hemophilia A cases and one hemophilia B case (Table 2).
- 3.2. Reasons for Amputation. Reasons for amputation varied among patients. The reasons for four amputations were variable (Table 2). Patient 1 accidently broke his left hip five

years after bilateral total hip arthroplasty (THA). In the local hospital, he was diagnosed with a left hip periprosthetic fracture, received factor VIII infusion with limb braking for two months. The fracture did not heal, and factor inhibitor (6.8 BU/ml) was the first time found for him. After six months' termination of factor replacement, the activity of the inhibitor decreased to 1.9 BU/ml, but the left thigh swelled significantly, which was a large pseudotumor with severe bone defects in radiograph (Figure 1). No conventional surgical technique except amputation could fix it. Patient 2 suffered a pathological fracture of the right femur caused by trauma. He received five months' bone traction at a local hospital. Two years later, a pseudotumor with bone defects was identified in the right inner thigh. In the next four years, he received twice resection of pseudotumor and one open reduction with allograft bone graft fixation of pathological fracture in the defected site. However, the fixation failed with the recurrence of pseudotumor. Methicillin-resistant Staphylococcus epidermidis was identified within wound secretion. The fracture, pseudotumor, and infection led to amputation (Figure 2(c)).

Patients 3 and 4 lost walking ability for years because of HO in knees. Patient 3 received regular factor replacement and developed two 3 cm ulcerative wounds on the right proximal tibia in the third year on the hospital bed. A surgical debridement attempt failed. Twelve years later, his right knee was fixed at a 90 angle (Figure 3). X-ray findings suggested a sinus between the wound and tibia bone marrow, indicating suspected chronic osteomyelitis (Figure 4). A similar 1 cm abrasion was found on the right inner thigh of Patient 4 after minor seizures for six years on the hospital bed. Two years later, the whole right lower limb began swelling and bleeding. Cultivation of wound secretions revealed the presence of Pseudomonas aeruginosa. Systematic application of antibiotics failed to control the persistent fever (37.5°C). Chronic infections were responsible for their amputations.

Among these four patients, the most common reasons for amputation were pseudotumor (3/4, 75%) and bacterial infection (3/4, 75%). The statistical analysis showed a significant difference of these factors between amputation and nonamputation cases (p=0.001). In cases reported in literature, hemophilic pseudotumor (24/27, 88.89%) and bacterial infection (14/27, 51.85%) were also common factors. There was only one amputation patient carried factor inhibitor in our four patients. However, he was the only inhibitor carrier among included patients. The previous amputation cases contained seven cases carrying inhibitor (25.93%), indicating that inhibitor could be another potential risk factor (Table 2).

3.3. Perioperative Treatment and Follow-Up. All amputation patients underwent coagulation factor replacement during perioperative period under the guidance of hematologists. Two patients received aboveknee amputation while hip disarticulation and high-thigh amputation were separately performed on the other two patients. The last follow-up assessment was conducted in June 2021 (Table S1). Patient 1

TABLE 1: Patient characteristics, management, and outcome of amputation cases.

	Outcome	Left hip wound unhealing, received debridement three times. The wound healed after 6 months' dressing, walking with crutches (3 years after amputation)	No complication, walking with crutches (3 years)	No complication, walking with crutches (1 year)	Transferred to ICU for 3 days after the operation, no postoperative complication; died from epilepsy two years after amputation
ABLE 1: Faucin characteristics, management, and outcome of amputation cases.	Amputation procedure	Disarticulation of left hip, right TKA	Above-knee amputation of right side	Above-knee amputation of right side	High-thigh amputation of right side
	Direct reason for amputation	Hemophilic pseudotumor with large bone defects (following periprosthetic fracture)	Pathological fracture, internal fixation failure, hemophilic pseudotumor with infection	Knee stiffness with chronic osteomyelitis	Hemophilic pseudotumor with systematic infection
	Management before amputation	Bilateral THA	Bone traction of right femoral fracture	Debridement of right knee ulcerative wounds	N/A
	Initial diagnosis of HO	Hemophilic arthritis of both hip and knee	Pathological fracture of right femur	Hemophilic arthritis with chronic osteomyelitis on right knee	Hemophilic pseudotumor of right thigh, with systematic infection
	Daily factor replacement	Regular replacement as secondary prophylaxis (FVIII 20,000 IU per year)	Inadequate secondary prophylaxis. (irregular FVIII injection on demand)	Regular primary prophylaxis (FVIII approx. 5,000 IU per year)	Regular primary prophylaxis (FVIII injection)
IABLE I	Duration until amputation	21 years	17 years	Since childhood (26 years)	Since childhood (24 years)
	Inhibitor	Yes, active (6.8 \longrightarrow 1.9 BU/ml)	% V	Ν̈́	No
	Type and severity	A, severe	A, severe	A, moderate	A, moderate
	Patient	-1	7	ϵ	4

Table 2: Risk factors summarized from amputation patients' records and their preferences in reported cases.

Risk factor		Amputation patients no.	All patients no.	P value	Frequency in reported cases
Homombilio most dotum on	Yes	3	21	0.00	48.15% (13/27)
Hemophilic pseudotumor	No	1	180	_	_
Infection	Yes	3	10	0.00	51.85% (14/27)
Illection	No	7	191	_	_
Factor inhibitor	Yes	1	1	N/A*	29.63% (8/27)
ractor infillibitor	No	200	200	_	_

 $^{^*}$ The statistical analysis was not performed for factor inhibitor because there was only one patient included.




FIGURE 1: X-ray photography of hip joints of Patient 1. (a) Taken two months after trauma. (b) Taken eight months after trauma, nearly the entire left femur displayed a characteristic "soap bubble" appearance, and the femoral stem "floated" in a large pseudotumor. (c) CT reconstruction (A) and general photography (B) taken eight months after trauma.



FIGURE 2: X-ray photography on the right femur of Patient 2. (a) The recurrent hemophilia pseudotumor before the second procedure (internal fixation with an allogeneic bone graft). (b) The postoperative situation of fracture fixation. (c) The collapse of internal fixation and recurrent pseudotumor two years after internal fixation.




FIGURE 3: (a) Lateral photography of Patient 3 in supine position before amputation. (b) Partial photography of posterior side of Patient 3's right knee.



FIGURE 4: X-ray photography on both knees of Patient 3 before amputation.

was the only patient suffered from severe postoperative complications. He used recombinant human factor VIIa (rhFVIIa) and human prothrombin complex concentrate (PCC) for perioperative replacement. The FVIII: I level was beyond the limit (>64 BU/ml) with progressive anemia (96 to 43 g/l) and increased wound drainage (40 to 230 ml/d);

thus, factor replacement was halted. In the next 63 days, he underwent three surgical debridement under intermittent factor replacement. Consequently, the inhibitor level decreased to 35.2 BU/ml. *Staphylococcus epidermidis* was once detected in wound secretions, so vancomycin was systematically applied. He was transferred to a local hospital 68 days







FIGURE 5: The healing situation of patients in the latest follow-up. (a) Patient 1 in 3 years after amputation. (b) Patient 2 in 3 years after amputation.

after amputation, and the incision healed completely after another 40 days of regular dressing. Patient 4 was transferred to the intensive care unit after surgery for three days due to a systematic infection. He recovered well and was discharged after the removal of stitches. Two years later, he died from a major epileptic event, which was found before the abrasion of the knee. In the last follow-up, all remaining patients reported no complaints, partly recovered self-care ability with crutches (Figure 5).

4. Discussion

At present, amputations are mainly used in chronic non-healing ulcers or severe infections [13, 14]. This paralytic operation reduces life quality, so limb salvage is usually the first choice [15]. Though significant progress has been recorded in surgical techniques for hemophiliacs, amputations are still the final option for some severe HO cases. However, to our knowledge, no report has specially investigated the reasons for amputation in hemophiliacs. Due to the low incidence, these amputations have only been reported in isolated case reports or studies with different aims (Table 3). The present study described four amputation cases of hemophilia patients who underwent surgical treatment in a single medical center with an average follow-up of 2 years.

Severe hemophilic pseudotumor was seen in three of our four cases, which is also common in previously reported amputation cases. Recurrent spontaneous bleeding promotes the enlargement of the hematoma, resulting in incredible limb swelling and disability. The circumference of the lower limb could be several times larger than the normal value (Figure 1(c)). In extreme cases, pseudotumor compression can cause severe compartmental syndrome [21]. Pathological fracture or osteolysis is seen in half of pseudotumor amputations (2/4 in the present study and 12/24 in previous reports). The fracture is often the initial pseudotumor cause or complication. Osteoporosis is a potential explanation for these fractures. The prevalence of bone mineral density (BMD) reduction can be up to 50%-80% in hemophiliacs [4]. Systematic analyses have suggested a relationship between low BMD and severe hemophilia, but precise mechanisms linking the conditions remain unclear

[28, 29]. Osteolysis is mainly seen in patients with massive or multiple pseudotumor. The loss of BMD is accompanied by shape deformation. In X-ray imaging, the affected bone has a characteristic bubble-like shape and the bone will finally disappear in the pseudotumor. The exact mechanism of the osteolysis remains unclear; inflammatory reactions during hematoma absorption may induce bone resorption. As a result of fracture and osteolysis, there is a high risk of recurrent internal/external fixation failure and fracture nonunion, leading to amputation. For patients with huge osteolytic defects, total femur replacement or custom-made prosthesis is applied in some limb salvage cases, but the longterm outcomes require further observation [30, 31]. Surgeons should be aware of unexplained swelling of extremities in hemophiliacs, especially the patients with a history of trauma or poor factor replacement. Adequate factor replacement is the first step in preventing bleeding and controlling pseudotumor. Based on the experience of Patient 1 in our study, we suggest regular radiology checks for osteolysis spaced at a time interval of no more than six months for patients with pseudotumor. The earlier discovery of osteolysis means a higher possibility of limb salvage. Perioperative and postoperative factor replacements are key factors affecting the success of surgical procedures in hemophiliacs; bleeding owing to inadequate replacement worsens the healing situation, and the acute hematoma may cause thrombosis via compression [27].

In the present study, the relationship between infection and amputation was highlighted. Abrasions or small wounds are common on swollen limbs with pseudotumor. Coagulation disorders make curating these wounds very hard, leaving them at high risk of chronic bacterial infection. The surgical removal of infection foci is a must for these patients. Control of coagulation disorder is the fundamental infection prevention solution. The replacement of infected joints is also a high-risk factor for amputation. A retrospective survey of the Danish population identified prosthetic joint infections as the most common cause of limb amputation after primary total knee arthroplasty [32]. Active cutaneous or deep tissue infections are important risk factors for prosthetic infections [33]. There are also reports of amputations in hemophiliacs caused by uncontrolled infection after knee

TABLE 3: Previous reported amputation cases.

Case number	Hemophilia type and main concomitant diseases	Musculoskeletal involvement	Surgical procedures	Reason for amputation
1 [11]	Moderate HA	Pathological fracture with HPT on right femoral shaft	Closed reduction and external fixation of right thigh; HPT excision with open reduction and internal fixation of tight thigh; high-thigh amputation	Pin infection, internal fixation failure, HPT recurrence
2 [11]	Severe HA	Pathological fracture with HPT on left femoral shaft Pathological fracture with HPT on	High-thigh amputation	Fracture and enlargement of HPT
3 [11]	Moderate HB	left femoral shaft; HPT on right femoral shaft with secondary pathological fracture on tight femoral shaft	Disarticulation of left hip; high-thigh amputation of right side	Fracture and enlargement of HPT
4 [9]	Severe HA	HPT, fracture of right femur	External fixation for femur fracture; Removal of external fixator, HPT excision and open reduction with internal fixation; amputation of left thigh at last	Nail infection, internal fixation failure
5 [9]	Mild HA	HPT, cutaneous fistulas and infection on thigh	Amputation of right thigh	Infection
6 [9]	Mild HA	HPT, cutaneous fistulas and infection on knee	Amputation of right thigh	Infection
7 [9]	Moderate HA with inhibitor	HPT with cutaneous fistulas and infection on left thigh	Amputation of left thigh	Infection
8 [9]	Severe HB	HPT with cutaneous fistulas and infection on both thigh and left knee	Left thigh amputation; right HPT excision; right thigh amputation	Infection for left thigh, HPT recurrence with osteolysis for right thigh
9 [9]	Moderate HA	HPT, cutaneous fistulas and infection on thigh	Amputation of left thigh	Infection
10 [9]	Moderate HA, with inhibitor	HPT, cutaneous fistulas and infection on left calf	Amputation of left calf	Infection
11 [9] 12 [9]	Severe HA Severe HA	Massive HPT on left thigh Massive HPT on right thigh	Amputation of left thigh Amputation of right thigh	Enlargement of HPT Enlargement of HPT
13 [16]	Moderate HA	Huge HPT with osteolysis on right femur	Hematoma evacuation, debridement and hip hemiarthroplasty; right hip dislocation	Wound infection with ulcer, hip prosthesis dislocation
14 [16]	Mild HA	Primary benign bone giant cell tumor on right distal fibula	Intralesional cottage (2 times); aboveknee amputation	Severe hematoma and wound dehiscence
15 [17]	Severe HA	HPT with osteolysis on distal phalanx of left little finger	Left little finger amputation	Persistent infection and enlargement of HPT
16 [17]	Severe HA	HPT with osteolysis on middle phalanx of left little finger	Left little finger amputation	Persistent infection and enlargement of HPT
17 [18]	N/A	Massive HPT on knee	Intralesional excision of pseudotumor with bone cement spacer	Pseudotumor recurrence after excision
18 [19]	Moderate HA	Pathological fracture, then recurrent HPT on left femur	implantation; above-knee amputation Open reduction and intramedullary fixation and a revision surgery; left lower limb amputation	Recurrent pseudotumor and persistent swelling of left limb
19 [19]	Severe HA with low titre of inhibitor	HPT on right tibia and fibula	Right lower limb amputation	Pain and arterial ulcer
20 [20]	HA, AIDS, hepatitis B and C	Huge HPT on right femur	Right hip dislocation	Hematoma enlargement with spontaneous bleeding, heart and kidney failure
21 [21]	Severe HA with high titre of inhibitor, hepatitis C, diabetic mellitus	Huge HPT and secondary compartment syndrome on left distal limb	Supracondylar amputation of left limb	Severe compartment syndrome with phlegmon

Table 3: Continued.

Case number	Hemophilia type and main concomitant diseases	Musculoskeletal involvement	Surgical procedures	Reason for amputation
22 [22]	Severe HA with high titre of inhibitor,	Hemophilia arthritis	Knee replacement of left side; revision of left knee; above-knee amputation of left knee	Uncontrolled infection after knee replacement
23 [23]	Severe HA	HPT with osteolysis on second metacarpal bone of right hand	Ray amputation of right index finger	Enlargement of HPT limited hand move
24 [24]	Severe HA	Multiple HPT with osteolysis on right femur, knee and tibia	Amputation of left lower limb	Enlargement of HPT and limitation of move
25 [25]	Severe HB with low titre of inhibitor	Multiple HPT with osteolysis of right proximal tibia and foot, with necrotic of left foot soft tissue	Transfemoral amputation of left lower limb	Enlargement of HPT with infection
26 [26]	Moderate HA with high titre of inhibitor	Pathological fracture followed by HPT on left tibia/fibula	Left knee disarticulation	Wound infection
27 [27]	Moderate HA	Hemophilia arthritis	Proximal tibial osteotomy of left side; Anterior and posterior fasciotomies; above-knee amputation	Deep venous thrombosis

HA, hemophilia A; HB, hemophilia B; HPT, hemophilic pseudotumor; N/A, not referred.

arthroplasty [22]. So, patients with chronic infection or unhealed wounds are not suitable for joint arthroplasty. Arthrodesis may be a safer choice to avoid amputation.

In all hemophiliacs included in the current study, Patient 1 was the only inhibitor carrier. Meanwhile, about a quarter of reported amputation cases had inhibitors, most of which underwent amputation as the first surgical treatment. It seems that hemophiliacs with inhibitors had higher possibility of amputation. The existence of inhibitors, antifactor antibodies, decreased the activity of coagulation factors, making hemostasis management difficult [34]. The etiology of developing factor inhibitors remains incompletely understood. Current evidence suggests a potential relationship between environmental factors (surgery, severe bleeds, and infections) and factor inhibitors [35]. Bypass agents such as rhFVIIa and PCC have adequate hemostatic effects and low rates of complications in surgical procedures involving inhibitor-positive patients [36-38]. Sufficient factor replacement plays a more important role in the perioperative management of hemophiliacs with factor inhibitors. Patient 1 in the present study was switched from rhFVIIa to PCC only three days after surgery for economic reasons. Then, he suffered from bleeding and incision complications. We advise that factor replacement via bypass agents should be extended.

There are some other risk factors for amputation. Most amputation patients are diagnosed with moderate or severe hemophilia A, indicating the influence of hemophilia type and severity. However, the prevalence of hemophilia A is about six times higher than that of hemophilia B, which may affect the incidence of severe HO and amputation. Socioeconomic factors also influence the amputation rate [1]. As we discussed above, sufficient factor replacement is important to prevent amputation. It is reported that 51% of people in high- and upper-middle-income countries use 94% and 92% of the total global quantity of factors VIII and IX, respectively [39]. For patients in developing countries, like Patient 2 in our study, regular replacement is still too

expensive. Megaprothesis for osteolysis is also costly; patient 1 in our study could not afford this. In the future, gene therapy might completely eradicate this hereditary disease, but economic issues will still be barriers for many patients [40].

The retrospective nature of this study is a limitation. Furthermore, this study involved a heterogeneous group, a small number of cases, and lacks a randomized control group. Considering that amputation is rare in hemophilia treatment, a multicenter review may provide additional evidence and enhance the meaningfulness of the result.

In general, amputation of the extremities is the last but necessary option for patients with severe HO. Severe hemophilic pseudotumor, chronic bacterial infection, and factor inhibitors are threatening risk factors for amputation in hemophiliacs. Sufficient factor replacement therapy is fundamental in the prevention of amputation. Early diagnosis of severe complications such as osteolysis and special surgical techniques such as total femur replacement could be useful in limb salvage.

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethical Approval

This retrospective study was approved by the Institutional Review Board at Peking Union Medical College Hospital with protocol number S-K1737.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

The authors thank Mr. Qinjiang Jing and Ms. Xueqing Wang for their help in database administration. This work was supported by the National Key R&D Program of China (grant no. 2018YFF0301105) and National Natural Science Foundation of China (grant no. 81630064).

Supplementary Materials

Table S1: perioperative and follow-up results for patients who received amputation. (Supplementary Materials)

References

- [1] E. Berntorp, K. Fischer, D. P. Hart et al., "Haemophilia," *Nature Reviews Disease Primers*, vol. 7, no. 1, p. 45, 2021.
- [2] R. Gualtierotti, L. P. Solimeno, and F. Peyvandi, "Hemophilic arthropathy: current knowledge and future perspectives," *Journal of Thrombosis and Haemostasis*, vol. 19, no. 9, pp. 2112–2121, 2021.
- [3] Z. Li and X. Weng, "Hemophilic pseudotumor," *New England Journal of Medicine*, vol. 382, no. 21, p. 2033, 2020.
- [4] P. Anagnostis, S. Karras, S. A. Paschou, and D. G. Goulis, "Haemophilia A and B as a cause for secondary osteoporosis and increased fracture risk," *Blood Coagulation and Fibrinolysis*, vol. 26, no. 6, pp. 599–603, 2015.
- [5] O. Katsarou, E. Terpos, P. Chatzismalis et al., "Increased bone resorption is implicated in the pathogenesis of bone loss in hemophiliacs: correlations with hemophilic arthropathy and HIV infection," *Annals of Hematology*, vol. 89, no. 1, pp. 67–74, 2010.
- [6] C.-Y. Chang, T.-Y. Li, S.-N. Cheng et al., "Prevalence and severity by age and other clinical correlates of haemophilic arthropathy of the elbow, knee and ankle among Taiwanese patients with haemophilia," *Haemophilia*, vol. 23, no. 2, pp. 284–291, 2017.
- [7] J. Ingerslev and I. Hvid, "Surgery in hemophilia. The general view: patient selection, timing, and preoperative assessment," *Seminars in Hematology*, vol. 43, no. 1 Suppl 1, pp. S23–S26, 2006.
- [8] C. R. Nacca, A. P. Harris, and J. R. Tuttle, "Hemophilic arthropathy," *Orthopedics*, vol. 40, no. 6, pp. e940–e946, 2017.
- [9] S. Lin, K. Tong, G. Wang, Z. Zhong, S. Cao, and Z. Feng, "Clinical characteristics and surgical treatment of haemophilic pseudotumor: a retrospective analysis of thirty-four patients," *Haemophilia*, vol. 26, no. 5, pp. 873–881, 2020.
- [10] J. L. Schuster, "Mid-thigh amputation in a hemophiliac," The Journal of Bone & Joint Surgery, vol. 36, no. 1, pp. 144-145, 1954.
- [11] K. Chen, G. Jiang, Y. Xu et al., "Surgical treatment for patients with hemophilic pseudotumor-related femoral fracture: a retrospective study," *Journal of Orthopaedic Surgery and Research*, vol. 16, no. 1, p. 275, 2021.
- [12] J. Zhai, X. Weng, B. Zhang, Y. Liu, P. Gao, and Y.-y. Bian, "Surgical treatment for hemophilic pseudotumor," *Journal of Bone and Joint Surgery*, vol. 99, no. 11, pp. 947–953, 2017.
- [13] K. Markatos, M. Karamanou, T. Saranteas, and A. F. Mavrogenis, "Hallmarks of amputation surgery," *International Orthopaedics*, vol. 43, no. 2, pp. 493–499, 2019.
- [14] N. Narula, A. J. Dannenberg, J. W. Olin et al., "Pathology of peripheral artery disease in patients with critical limb

- ischemia," Journal of the American College of Cardiology, vol. 72, no. 18, pp. 2152–2163, 2018.
- [15] S. P. Ryan, M. DiLallo, M. R. Klement, A. J. Luzzi, A. F. Chen, and T. M. Seyler, "Transfemoral amputation following total knee arthroplasty," *The Bone & Joint Journal*, vol. 101-b, no. 2, pp. 221–226, 2019.
- [16] A. F Kamal, A Waryudi, A Kurniawan, A. M Lubis, and D Gatot, "Various surgical treatment of hemophilic pseudotumor: a case series," *The Archives of Bone and Joint Surgery*, vol. 7, no. 6, pp. 514–522, 2019.
- [17] B. P. Thomas, N. A. Fouzia, S. Raveendran, S. R. Pallapati, A. Abraham, and A. Srivastava, "Management of hemophilic cysts and pseudotumors of the hand in bleeding disorders: a case series," *The Journal of Hand Surgery*, vol. 43, no. 5, pp. 486.e1–486.e9, 2018.
- [18] Y. Sunnassee, R. Wan, Y. Shen, J. Xu, E. P. Southern, and W. Zhang, "Preliminary results for the use of knee megaendoprosthesis in the treatment of musculoskeletal complications of haemophilia," *Haemophilia*, vol. 21, no. 2, pp. 258–265, 2015.
- [19] M. Y. Lim, B. Nielsen, A. Ma, and N. S. Key, "Clinical features and management of haemophilic pseudotumours: a single US centre experience over a 30-year period," *Haemophilia*, vol. 20, no. 1, pp. e58–e62, 2014.
- [20] B. Liu, L. Liu, Y. Feng, and L. Li, "A case report on the surgical treatment of the huge inflammatory pseudotumor in the AIDS patient with hemophilic," *Case Reports in Pathology*, vol. 2011, Article ID 798649, 4 pages, 2011.
- [21] N. Rajic, A. Savic, S. Popovic, I. Urosevic, and I. Savic, "Successful control of bleeding during supracondylar amputation caused by severe compartment syndrome in patient with haemophilia A and high titre of inhibitor," *Haemophilia*, vol. 15, no. 2, pp. 601-602, 2009.
- [22] L. P Ho, Y. K Ho, and S. L Tien, "Case report: induction of immune tolerance to factor VIII inhibitor after a major operation," *Annals Academy of Medicine Singapore*, vol. 36, no. 6, pp. 431–434, 2007.
- [23] A. D. Gupta, A. Bose, and D. Mahalanabis, "Haemophilic pseudotumour involving the right second metacarpal bone in a 5-year-old boy, treated by ray amputation," *Haemophilia*, vol. 10, no. 4, pp. 408-409, 2004.
- [24] J. M. Stafford, T. T. James, A. M. Allen, and L. R. Dixon, "Hemophilic pseudotumor: radiologic-pathologic correlation," *RadioGraphics*, vol. 23, no. 4, pp. 852–856, 2003.
- [25] M. Heim, H. Horoszowski, S. Schulman et al., "Multifocal pseudotumour in a single limb," *Haemophilia*, vol. 3, no. 1, pp. 50–53, 1997.
- [26] A. Chuansumrit, P. Hathirat, S. Keorochana et al., "Disarticulation of a knee joint in a haemophiliac with high inhibitor titre," *Haemophilia*, vol. 2, no. 2, pp. 116–119, 1996.
- [27] B. Ritchie, R. C. Woodman, and M.-C. Poon, "Deep venous thrombosis in hemophilia A," *The American Journal of Medicine*, vol. 93, no. 6, pp. 699-700, 1992.
- [28] A. Gaudio, A. Xourafa, R. Rapisarda, L. Zanoli, S. S. Signorelli, and P. Castellino, "Hematological diseases and osteoporosis," *International Journal of Molecular Sciences*, vol. 21, no. 10, p. 3538, 2020.
- [29] E. C. Rodriguez-Merchan and L. A. Valentino, "Increased bone resorption in hemophilia," *Blood Reviews*, vol. 33, pp. 6–10, 2019.
- [30] J. M. Buchowski, B. M. Cascio, M. B. Streiff, and F. J. Frassica, "Resection and reconstruction of a massive femoral hemophilic pseudotumor," *Clinical Orthopaedics and Related Research*, vol. 430, pp. 237–242, 2005.

- [31] U. C. Stumpf, C. Eberhardt, and A. A. Kurth, "Orthopaedic limb salvage with a mega prosthesis in a patient with haemophilia A and inhibitors? a case report," *Haemophilia*, vol. 13, no. 4, pp. 435–439, 2007.
- [32] T. B. Gottfriedsen, H. M. Schrøder, and A. Odgaard, "Transfemoral amputation after failure of knee arthroplasty," *Journal of Bone and Joint Surgery*, vol. 98, no. 23, pp. 1962–1969, 2016.
- [33] B. H. Kapadia, R. A. Berg, J. A. Daley, J. Fritz, A. Bhave, and M. A. Mont, "Periprosthetic joint infection," *The Lancet*, vol. 387, no. 10016, pp. 386–394, 2016.
- [34] S. Merlin and A. Follenzi, "Escape or fight: inhibitors in hemophilia A," *Frontiers in Immunology*, vol. 11, p. 476, 2020.
- [35] I. Garagiola, R. Palla, and F. Peyvandi, "Risk factors for inhibitor development in severe hemophilia a," *Thrombosis Research*, vol. 168, pp. 20–27, 2018.
- [36] C. Carulli, M. Innocenti, S. Linari, M. Morfini, G. Castaman, and M. Innocenti, "Joint replacement for the management of haemophilic arthropathy in patients with inhibitors: a long-term experience at a single Haemophilia centre," *Haemophilia*, vol. 27, no. 1, pp. e93–e101, 2021.
- [37] D. Lillicrap, K. Fijnvandraat, G. Young, and M. E. Mancuso, "Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms," *Expert Review of Hematology*, vol. 13, no. 4, pp. 313–321, 2020.
- [38] E. Santagostino, M. Escobar, M. Ozelo et al., "Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors," *Blood Reviews*, vol. 29, pp. S9–S18, 2015.
- [39] J. S. Stonebraker, P. H. B. Bolton-Maggs, M. Brooker et al., "The world federation of hemophilia annual global survey 1999–2018," *Haemophilia*, vol. 26, no. 4, pp. 591–600, 2020.
- [40] G. Q. Perrin, R. W. Herzog, and D. M. Markusic, "Update on clinical gene therapy for hemophilia," *Blood*, vol. 133, no. 5, pp. 407–414, 2019.